Researchers aimed to investigate how different tumor types can influence the prevalence of severe SARS-CoV-2 and case-fatality rate. It was determined that tumor type does have an effect on how susceptible one is to SARS-CoV-2 and the disease phenotypes that result. In particular, COVID-19 patients with hematological cancers, such as myeloma, leukemia, and lymphoma, appeared to be at higher risk of exhibiting more severe clinical outcomes, needed more intense support interventions, and were more likely to die than COVID-19 patients with malignancies that were not hematological.

COVID-19 patients with lung or prostate cancer did not exhibit a higher case-fatality rate than the other COVID-19 patients with other cancer types. In addition, patients with malignancies in the female genital tract or with breast cancers seemed to be at a decreased risk of being infected with COVID-19 or dying from the virus, but this protection is rather a result of the patients being female, as indicated by a multivariable analysis conducted.